XTalks

OCTOBER 24, 2024

Trends in Psoriasis Research: Biologics, Biosimilars and New Therapies Recent innovations in biologics and biosimilars have transformed psoriasis care. The Psoriasis Diet Diet has long been an area of research as a potential factor in managing psoriasis.

Research 105

Research Dermatology Clinical Trials Clinical Trials 105

Cloudbyz

AUGUST 7, 2024

In general, the total number of initiated clinical trials dropped by about 25% , where the reduction in the research applied in the fields of dermatology and lifestyle amounted to about 20%. Investments on research of cancer continued while the oncology trials gained 5%. Rare disease trials decreased by 30%.

Clinical Research 52

Clinical Research Clinical Trials Clinical Trials Research 52

Olympian Clinical Research

FEBRUARY 13, 2024

At Academic Alliance in Dermatology, we understand the importance of using products that not only care for your skin on the surface but also work effectively at a cellular level. Precision Formulation Medical Grade Skincare Designed with precision, medical-grade products contain higher concentrations of active ingredients.

Production 52

Production Dermatology Branding Containment 52

Olympian Clinical Research

MARCH 1, 2024

If you are wondering how to remove age spots, Academic Alliance in Dermatology can help. Ways to Remove Age Spots At Academic Alliance in Dermatology, we specialize in advanced, professional treatments to effectively reduce age spots, ensuring our patients receive the highest standard of care. What are Age Spots?

Dermatology 52

Dermatology Production Cosmetics Hormones 52

The Pharma Data

JULY 8, 2021

KEYTRUDA has shown meaningful efficacy in patients with locally advanced or recurrent or metastatic cutaneous squamous cell carcinoma that cannot be cured by surgery or radiation,” said Dr. Vicki Goodman, vice president, clinical research, Merck Research Laboratories. 1) as determined by an FDA-approved test.

FDA Approval 52

FDA Approval Containment Trials Genomics 52

The Pharma Data

MARCH 23, 2021

Immune-mediated adverse reactions can occur at any time during or after treatment with KEYTRUDA, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic reactions, solid organ transplant rejection, and complications of allogeneic hematopoietic stem cell transplantation. 1] as determined by an FDA-approved test.

HR 52

HR FDA Approval Containment Genomics 52

The Pharma Data

APRIL 4, 2023

Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with Padcev (enfortumab vedotin-ejfv) for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who are not eligible for cisplatin-containing chemotherapy.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40